Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Aurigene Partners with Edity for Cell Therapy Discovery Services to Accelerate Clinical Development

NextEdge Admin

03 Jul 2024

2 min 22 sec

gene therapy,Cell therapy,autoimmune disorders,regenerative medicine

Aurigene Pharmaceutical Services, an India-based contract research, development, and manufacturing organization (CRO/CDMO), announced on July 1, 2024, a partnership with Israel-based Edity Therapeutics. This collaboration aims to advance cell therapy discovery services, leveraging Edity’s innovative immune cell delivery platform. Edity focuses on precise intracellular protein delivery to target cells with high specificity, crucial for therapies in oncology, gene therapy, autoimmune disorders, and regenerative medicine.

The agreement follows an initial strategic collaboration started between Edity and Aurigene’s parent company, Dr. Reddy’s Laboratories, in January 2024. Aurigene, known for its expertise in biologics and advanced therapies such as antibodies, antibody-drug conjugates (ADCs), and viral vectors, will now extend its capabilities to support Edity’s novel technologies. This includes enhancing the efficacy of CAR-T cell therapeutics through Edity’s cellular reprogramming approach.

Roger Lias, Aurigene’s global commercial head of biologics, highlighted their comprehensive service offering—from discovery through large-scale CGMP manufacture—as pivotal in delivering high-quality and economically viable solutions. This aligns with Aurigene’s strategic focus on cost-effective manufacturing of both small molecules and biologics.

Edity’s CEO, Michal Golan Mashiach, expressed enthusiasm about collaborating with Aurigene’s team, expecting their technological breadth and experience to accelerate Edity’s pipeline development. The partnership aims to address challenges in solid tumor therapy, including antigen heterogeneity and the immunosuppressive tumor microenvironment.

The alliance underscores Aurigene’s role as a preferred partner in global biologics and advanced therapies, dedicated to advancing innovative treatments and ultimately improving patient outcomes across severe diseases.